VIGL

Vigil Neuroscience (VIGL)

Vigil Neuroscience Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VIGL

1 2 3 4 5 6 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/09	06 : 05	GlobeNewswire Inc.	Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/12/20	08 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/11/15	00 : 00	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/11/12	21 : 00	GlobeNewswire Inc.	Vigil Neuroscience to Present at Upcoming Investor Conferences	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/11/07	21 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/11/07	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/11/07	21 : 00	GlobeNewswire Inc.	Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/11/05	21 : 00	GlobeNewswire Inc.	Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/10/10	07 : 22	Edgar (US Regulatory)	Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/09/20	06 : 20	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/09/17	20 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/09/17	20 : 00	GlobeNewswire Inc.	Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/09/17	05 : 05	GlobeNewswire Inc.	Vigil Neuroscience to Present at Cantor Global Healthcare Conference	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/08/29	20 : 00	GlobeNewswire Inc.	Vigil Neuroscience to Present at Upcoming September Investor Conferences	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/08/13	20 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/08/13	20 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/08/13	20 : 00	GlobeNewswire Inc.	Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/08/13	06 : 02	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/08/02	05 : 05	GlobeNewswire Inc.	Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/07/31	05 : 05	GlobeNewswire Inc.	Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/07/24	20 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/07/24	20 : 00	GlobeNewswire Inc.	Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/07/19	05 : 05	GlobeNewswire Inc.	Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/07/18	20 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/07/18	20 : 00	GlobeNewswire Inc.	Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/06/27	15 : 00	GlobeNewswire Inc.	Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/06/08	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/06/08	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/06/07	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VIGL	Vigil Neuroscience Inc
2024/05/30	20 : 05	GlobeNewswire Inc.	Vigil Neuroscience to Present in Upcoming June Investor Conferences	NASDAQ:VIGL	Vigil Neuroscience Inc